Company: AEMD
Filing Date: 2025-02-12
Form Type: 10-Q
Source: 0001683168-25-000960
Chunk: 67

Company: AETHLON MEDICAL INC
Filing Date: 2025-02-12
Form: 10-Q
Item: Item 8
Chunk 67
---
 shares, respectively, for additional total proceeds of $1,844,400. See the section entitled “May 2024 Public
Offering,” below, for additional information regarding this offering.

We do not expect our existing cash as of December
31, 2024 to be sufficient to fund our operations for at least twelve months from the issuance date of these financial statements. Significant
additional financing must be obtained to provide a sufficient source of operating capital and to allow us to continue to operate as a
going concern.  We intend to fund operations, working capital and other cash requirements for the twelve-month period subsequent
to December 31, 2024 through a combination of debt and/or equity financing arrangements and potentially from collaborations or strategic
partnerships.

As we expand our activities, our overhead costs
to support personnel, laboratory materials and infrastructure will increase and significant additional financing must be obtained to provide
a sufficient source of operating capital. Should the financing we require to sustain our working capital needs be unavailable to us on
reasonable terms, if at all, when we require it, we may be unable to support our research and our planned clinical trials. The failure
to implement our research and clinical trials would have a material adverse effect on our ability to conduct planned clinical trials and
commercialize our products.

Future capital requirements will depend upon many
factors, including progress with pre-clinical testing and clinical trials, the number and breadth of our clinical programs, the time and
costs involved in preparing, filing, prosecuting, maintaining and enforcing patent claims and other proprietary rights, the time and costs
involved in obtaining regulatory approvals, competing technological and market developments, as well as our ability to establish collaborative
arrangements, effective commercialization, marketing activities and other arrangements. We expect to continue to incur increasing negative
cash flows and net losses for the foreseeable future.

Going Concern

The accompanying unaudited
condensed consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates,
among other things, the realization of assets and satisfaction of liabilities in the ordinary course of business. We have incurred continuing
losses from operations and at December 31, 2024 had limited working capital and an accumulated deficit of $161,699,924. These factors,
among other matters, raise substantial doubt about our ability to continue as a going concern within one year of the date of the financial
statements included in this Quarterly Report. A significant amount of additional capital will be necessary to advance the